| Journal | Clinical rheumatology |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
This review critically evaluates the therapeutic role of cannabis and its derivatives in managing osteoarthritic pain, with a focus on clinical evidence and efficacy of various pharmacological dose and forms. A literature search was conducted using Medline, EMBASE, CINAHL and COCHRANE databases with the key terms “cannabis”, “cannabidiol”, “CBD”, “osteoarthritis” and “human”. Inclusion criteria were limited to studies published in English with full-text access from year 2020 onwards; animal-based laboratory research, narrative surveys, and questionnaire-based studies were excluded. Out of 517 search results, 19 were included in this review. Initial clinical studies using different CBD formulations and dosages suggest potential benefits for relieving OA symptoms, with topical CBD showing the most encouraging results and an acceptable safety profile. Nonetheless, the overall strength of the evidence is constrained by considerable variability in CBD dosing and product types, as well as th
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
